

Smart Oncology Network (SONet)

What is the Roche-Celo Innovation Partnership?

In October 2017 Roche entered into an Innovation Partnership with Celo Limited, a NZ company, (<https://www.celohealth.com/product/>) to facilitate the introduction of the Celo healthcare secure messaging platform (Celo App) to research and clinical professionals active in the field of oncology.

The Innovation Partnership allows Roche and Celo to collaborate in the development of new functionality for the Celo App to make it more attractive to oncologists and cancer researchers. Part of the investment from Roche is used to pay for development time and in return Roche has a voice in the discussion on prioritisation of new features.

Benefits to Celo

- New use cases (research and clinical trial teams)
- Collaboration with a Professional Society
- Increased user numbers
- New customer and revenue
- Development feedback from users and NZSO

Benefits to Roche

- Partnership with NZSO
- Supporting improved patient outcomes
- Facilitating a digital oncology network in NZ
- Input into prioritisation of new features
- Association with Celo and publicity
- Leadership in digital healthcare

Duration of the Innovation Partnership

The Innovation Partnership between Roche and Celo is for 2 years initially.

The success of the SONet Project is dependent on uptake, use and feedback from participating research groups. Enthusiastic uptake will result in Roche continuing with the Partnership for the full 2 years. In this case Celo will promote the success of the SONet project to the users' employers with the aim of securing institutional subscriptions and ongoing access to the Celo App. This strategy is a part of Celo's business plan and will begin at the same time as the SONet Project.

SONet Project review meetings will take place every 6 months to consider the feedback from participating research groups, to review use metrics, and hear updates on Celo's progress with its business plan. Every participating research group will have the right to representation at the 6-monthly review meetings.

The Future of a Smart Oncology Network in New Zealand

The digital revolution is here.

A fully connected network of oncologists, clinical trial investigators and cancer researchers could:

- Enhance patient care through efficient decision-making and sharing of innovative processes
- Simplify clinical trial site selection and participant recruitment
- Eliminate distance and location as a barrier to group interactions and participation
- Facilitate sharing and discussion of new clinical data and interaction with colleagues and industry partners in a convenient and non-intrusive way
- Simplify delivery of medical education; delivered directly to a device to be viewed when it suits the user

Roche is excited to be part of the digital revolution in NZ healthcare